Cited by 42Epilepsy research and treatmentTraumatic Brain Injury ResearchAlzheimer's disease research and treatments

Tau deposition in young adults with drug-resistant focal epilepsy.

Open access
Smith, Kelsey M., Blessing, Melissa M., Parisi, Joseph E., Britton, Jeffrey W., Mandrekar, Jay, Cascino, Gregory D.·2019·Epilepsia

Abstract

OBJECTIVE: To evaluate the presence of tau deposition and pathologic features of chronic traumatic encephalopathy (CTE) in young adult patients treated with focal cortical resections for drug-resistant epilepsy. METHODS: Sixty consecutive patients who had undergone surgical treatment for drug-resistant focal epilepsy between 18 and 45 years of age were identified (2010-2017). Medical records were reviewed to determine clinical factors, including history of head trauma, age at seizure onset, age at surgical resection, seizure type(s) and frequency, imaging findings, and surgical outcome. All formalin-fixed, paraffin-embedded blocks from the surgical specimens from each subject were sectioned and stained with hematoxylin and eosin and antibodies to tau (Thermo Fisher Scientific Clone AT8), and examined blindly for tau pathology, including lesions characteristic of CTE. RESULTS: The median age at resection was 29.5 years (range = 19-45). A history of head trauma was reported in 19 patients. Although none of the patients had pathological findings characteristic of CTE, 23 patients (38%) demonstrated tau-immunoreactive lesions, including neurites, neurofibrillary pretangles, neurofibrillary tangles, subpial tau, and/or glial tau. In 4 of the 23 patients (7% of the cohort; 17% of those with tau pathology), substantial tau burden was identified. Three of these 4 patients had no significant history of head trauma; 1 patient had multiple sports-related concussions. No specific clinical factors correlated with the presence of tau pathology. SIGNIFICANCE: Tau-immunoreactive lesions were found in 38% of 60 patients who underwent a focal cortical resection for drug-resistant focal epilepsy. Diagnostic features of CTE were not detected in any patient; however, the pathological evaluation for CTE was limited to a surgical specimen. The prominent and excessive tau deposition in 23 patients (38%) is abnormal in this age group and warrants further investigation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/epi.16375

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The presence of tau pathology in childhood or adolescent-onset epilepsies and in relatively younger temporal lobe epilepsy patient cohorts suggests a causal link between seizure activity and p-tau accumulation.

    “However, the presence of tau pathology in childhood or adolescent-onset epilepsies, such as Dravet syndrome, Nodding syndrome, Lafora disease, NPC, TSC, and ASD, and in relatively younger TLE patient cohorts (Puvenna et al., 2016; Smith et al., 2019; Gourmaud et al., 2020) suggest a causal link between seizure activity and p-tau accumulation.”

    From Tauopathy and Epilepsy Comorbidities and Underlying Mechanisms (2022) · cites this paper as Smith et al., 2019

    The Discussion (page not provided) reports tau deposition in 38% of a younger cohort with drug-resistant focal epilepsy, supporting the younger-patient portion of the claim. It does not establish a causal link between seizures and p-tau accumulation: the authors say further study is needed to determine whether tau contributes to epilepsy, follows seizure activity, or develops in parallel. This study did not examine the listed childhood-onset syndromes. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • Observations of subpial bands formed by cortical p-tau depositions have been made across separate studies, providing evidence for a novel pattern of tau pathology in temporal lobe epilepsy that may result from seizure-induced reorganization of temporal lobe networks.

    “Interestingly, observations of subpial bands formed by cortical p-tau depositions have been made across separate studies (Puvenna et al., 2016; Tai et al., 2016; Smith et al., 2019), providing evidence for a novel pattern of tau pathology in TLE that may result from seizure-induced reorganization of temporal lobe networks (Tai et al., 2018).”

    From Tauopathy and Epilepsy Comorbidities and Underlying Mechanisms (2022) · cites this paper as Smith et al., 2019

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 16

  1. [1]Schmidt D, Schachter SC. Drug treatment of epilepsy in adults. BMJ. 2014; 348: g254. 24583319
  2. [2]Kwan P, Schachter SC, Brodie MJ. Drug‐resistant epilepsy. N Engl J Med. 2011; 365: 919– 26. 21899452
  3. [3]Miller LA, Galioto R, Tremont G, et al. Cognitive impairment in older adults with epilepsy: characterization and risk factor analysis. Epilepsy Behav. 2016; 56: 113– 7. 26859320
  4. [4]Tai XY, Bernhardt B, Thom M, et al. Review: Neurodegenerative processes in temporal lobe epilepsy with hippocampal sclerosis: clinical, pathological and neuroimaging evidence. Neuropathol Appl Neurobiol. 2018; 44: 70– 90. 29288503
  5. [5]Perrine K, Helcer J, Tsiouris AJ, Pisapia DJ, Stieg P. The current status of research on chronic traumatic encephalopathy. World Neurosurg. 2017; 102: 533– 44. 28254594
  6. [6]Lin JJ, Mula M, Hermann BP. Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. Lancet. 2012; 380: 1180– 92. 23021287 PMC3838617
  7. [7]Korczyn AD, Schachter SC, Brodie MJ, et al. Epilepsy, cognition, and neuropsychiatry (Epilepsy, Brain, and Mind, part 2). Epilepsy Behav. 2013; 28: 283– 302. 23764496 PMC5016028
  8. [9]Jones AL, Britton JW, Blessing MM, Parisi JE, Cascino GD. Chronic traumatic encephalopathy in an epilepsy surgery cohort: clinical and pathologic findings. Neurology. 2018; 90: e474– 8. 29321231
  9. [10]Tai XY, Koepp M, Duncan JS, et al. Hyperphosphorylated tau in patients with refractory epilepsy correlates with cognitive decline: a study of temporal lobe resections. Brain. 2016; 139: 2441– 55. 27497924 PMC5926008
  10. [11]Thom M, Liu JY, Thompson P, et al. Neurofibrillary tangle pathology and Braak staging in chronic epilepsy in relation to traumatic brain injury and hippocampal sclerosis: a post‐mortem study. Brain. 2011; 134: 2969– 81. 21903728 PMC3187539
  11. [14]Engel J Jr. Surgical Treatment of the Epilepsies. New York, NY: Raven Press; 1993.
  12. [16]Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011; 70: 960– 9. 22002422
  13. [17]Xi ZQ, Wang XF, Shu XF, et al. Is intractable epilepsy a tauopathy? Med Hypotheses. 2011; 76: 897– 900. 21440375
  14. [18]Holth JK, Bomben VC, Reed JG, et al. Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy. J Neurosci. 2013; 33: 1651– 9. 23345237 PMC3711605
  15. [19]Amatniek JC, Hauser WA, DelCastillo‐Castaneda C, et al. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia. 2006; 47: 867– 72. 16686651
  16. [20]Simic G, Babic Leko M, Wray S, et al. Tau protein hyperphosphorylation and aggregation in Alzheimer's disease and other tauopathies, and possible neuroprotective strategies. Biomolecules. 2016; 6: 6. 26751493 PMC4808800

Cited by

Sorted by citations

Authors
Smith, K. M., Blessing, M. M., Parisi, J. E., Britton, J. W., Mandrekar, J., & Cascino, G. D.
Affiliations
Mayo Clinic (US)
Corresponding author
Cascino, Gregory D.
Venue
Epilepsia
Publisher
Wiley
Published
2019-10-29
Volume
60
Issue
12
Pages
2398-2403
ISSN
  • 0013-9580 (ISSN-L)
  • 1528-1167
OpenAlex
W2982423301
Cited by
42
References
4
Citations by year
2026: 6 · 2025: 6 · 2024: 9 · 2023: 6 · 2022: 4 · 2021: 8 · 2020: 3
FWCI
2.99
Type
journal article
Language
en
Open access
Locations
  • Epilepsia (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Mayo Foundation for Medical Education and Research
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Epilepsy research and treatment
  • Health Sciences › Medicine › Epidemiology › Traumatic Brain Injury Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
tau deposition, drug-resistant focal epilepsy, chronic traumatic encephalopathy, neurofibrillary tangles, young adults, head trauma, sports-related concussion
MeSH terms
Drug Resistant Epilepsy, Adult, Brain, Brain Chemistry, Epilepsies, Partial, Humans, Middle Aged, tau Proteins, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review